Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-1162
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABBV-1162 is an investigational drug candidate being developed by AbbVie. It is currently in early-stage clinical development, with its safety, tolerability, and pharmacokinetics being evaluated in a Phase 1, double-blind, placebo-controlled, first-in-human trial involving healthy adult subjects who receive single ascending oral doses of the compound. Detailed information regarding its specific molecular target, mechanism of action, and primary therapeutic indications has not yet been publicly disclosed.
Beyond the preview
Go deeper on ABBV-1162.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-1162.